Fosun Global Partner, Executive President of Fosun Pharma, President of Global R&D & Chief Medical Officer and Chair of the Scientific Committee of Fosun Pharma；Co-President of Fosun Pharma Industrial Development Co.; Director of Shanghai Key Laboratory of Stem Cell Therapy; He served as the Deputy Director of the Academic Committee of the 5th Chinese Conference on Oncology and Former global Vice-President of Clinical Development Oncology at Sanofi.
Dr. Hui has 30 years of experiences in cancer treatment and innovative drug development in world's top medical centers and pharmaceutical companies. He has led the global development and registration of multiple small molecule and biologic anti-cancer drugs including Ixazomib, Isatuximab (anti-CD38) et al. Dr. Hui has published nearly 90 peer-reviewed articles on top scientific journals including The New England Journal of Medicine, The Lancet and Cancer Cell, et al. He has recently led the deal of the joint development, registration and launch of mRNA new coronavirus vaccine -FUBITAI between BioNTech and Fosun Pharma.